These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20187712)

  • 41. AChR-specific immunosuppressive therapy of myasthenia gravis.
    Luo J; Lindstrom J
    Biochem Pharmacol; 2015 Oct; 97(4):609-619. PubMed ID: 26215875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.
    Mané-Damas M; Molenaar PC; Ulrichts P; Marcuse F; De Baets MH; Martinez-Martinez P; Losen M
    Autoimmun Rev; 2022 Jul; 21(7):103104. PubMed ID: 35452851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autoimmune diseases against cell surface receptors: myasthenia gravis, a prototype anti-receptor disease.
    De Baets MH
    Neth J Med; 1994 Dec; 45(6):294-301. PubMed ID: 7838246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical evaluation and management of myasthenia gravis.
    Keesey JC
    Muscle Nerve; 2004 Apr; 29(4):484-505. PubMed ID: 15052614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autoimmune mechanisms in myasthenia gravis.
    Cavalcante P; Bernasconi P; Mantegazza R
    Curr Opin Neurol; 2012 Oct; 25(5):621-9. PubMed ID: 22941261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Contribution of intravenous immunoglobulins to the treatment of myasthenia].
    Gajdos P
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S30-4. PubMed ID: 10896986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of myasthenia gravis.
    Saperstein DS; Barohn RJ
    Semin Neurol; 2004 Mar; 24(1):41-8. PubMed ID: 15229791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci.
    Protopapadakis E; Kokla A; Tzartos SJ; Mamalaki A
    Eur J Immunol; 2005 Jun; 35(6):1960-8. PubMed ID: 15915538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of seronegative myasthenia garvis].
    Motomura M
    Rinsho Shinkeigaku; 2007 Nov; 47(11):877-9. PubMed ID: 18210824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunotherapy for autoimmune autonomic ganglionopathy.
    Iodice V; Kimpinski K; Vernino S; Sandroni P; Low PA
    Auton Neurosci; 2009 Mar; 146(1-2):22-5. PubMed ID: 19056323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Recent advancement in the basic and clinical studies in myasthenia gravis].
    Okumura M; Shiono H
    Kyobu Geka; 2011 Jan; 64(1):79-89. PubMed ID: 21229683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients.
    Basile U; Marino M; Napodano C; Pocino K; Alboini PE; Gulli F; Evoli A; Provenzano C; Bartoccioni E
    J Immunol Res; 2018; 2018():9646209. PubMed ID: 29765992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scale up and safety parameters of antigen specific immunoadsorption of human anti-acetylcholine receptor antibodies.
    Lagoumintzis G; Zisimopoulou P; Trakas N; Grapsa E; Poulas K; Tzartos SJ
    J Neuroimmunol; 2014 Feb; 267(1-2):1-6. PubMed ID: 24412396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conventional and emerging treatments and controversies in myasthenia gravis.
    Evoli A; Damato V
    Expert Rev Neurother; 2023 May; 23(5):445-456. PubMed ID: 37102669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [DFPP in myasthenia gravis: case report].
    Altobelli C; Pollastro RM; Marano E; Capasso G; Anastasio P
    G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment principles in the management of autoimmune myasthenia gravis.
    Richman DP; Agius MA
    Ann N Y Acad Sci; 2003 Sep; 998():457-72. PubMed ID: 14592915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.
    Behin A; Le Panse R
    J Neuromuscul Dis; 2018; 5(3):265-277. PubMed ID: 30010142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W; Bucka C; Klingel R
    J Clin Apher; 2011 Dec; 26(6):347-55. PubMed ID: 22095647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myasthenia gravis. Pathogenesis and current concepts in management.
    Havard CW; Scadding GK
    Drugs; 1983 Aug; 26(2):174-84. PubMed ID: 6884241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis.
    Wang J; Xiao Y; Zhang K; Luo B; Shen C
    Neuroscience; 2018 Mar; 374():264-270. PubMed ID: 29421431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.